Customize ugt-55 Antibody

Description

Identification of "ugt-55 Antibody"

The term "ugt-55" does not correspond to any recognized isoform of the UDP-glucuronosyltransferase (UGT) enzyme family or a validated antibody target. UGTs are classified into numbered subfamilies (e.g., UGT1A, UGT2B) with specific isoforms (e.g., UGT2B15, UGT1A1) . The nomenclature "ugt-55" is inconsistent with established UGT naming conventions, which use alphanumeric identifiers (e.g., UGT2B15, UGT1A8) .

Typographical or Nomenclature Errors

The term may reference a hypothetical or mislabeled entry. For example:
- UGT2B15 (UniProt ID P54855) is a well-characterized UGT isoform involved in steroid metabolism and drug detoxification .
- UGT1A1 (UniProt ID P22309) is critical for bilirubin conjugation .
Commercial antibodies often use catalog numbers (e.g., ab89274 for UGT2B15 or #4371 for a general UGT antibody ) rather than "ugt-55."

Experimental or Proprietary Designations

If "ugt-55" refers to an unpublished or proprietary antibody, it would not appear in public databases.

Related UGT Antibodies and Research Findings

While "ugt-55 Antibody" is unverified, below are key findings for validated UGT antibodies and their roles in research:

Validated UGT Antibodies

Antibody Target	Catalog ID	Applications	Key Research Findings
UGT2B15	ab89274 (Abcam)	WB, Drug Metabolism	Conjugates androgens, estrogens, and xenobiotics; linked to cancer drug resistance .
UGT1A1	N/A	Metabolic Studies	Critical for bilirubin detoxification; polymorphisms cause hyperbilirubinemia .
Pan-UGT	#4371 (CST)	WB	Detects endogenous UGTs (~55–60 kDa) across species .

Functional Insights from UGT Research

UGT2B17: Elevated in chronic lymphocytic leukemia (CLL), associated with fludarabine resistance .
UGT1A Enzymes: Inactivate chemotherapeutics like SN-38 (irinotecan metabolite) via glucuronidation .
UGT2A1: Expressed in aerodigestive tract tissues; SNPs alter carcinogen metabolism .

Recommendations for Further Inquiry

Verify Target Specificity: Confirm whether "ugt-55" refers to a typo (e.g., UGT1A1, UGT2B15) or a novel target.
Consult Specialized Databases:
- UniProt: For validated UGT isoforms.
- PubMed: For recent studies on uncharacterized UGTs.
- Antibody Vendors: Search catalogs using alternate nomenclature.

Limitations of Current Data

No peer-reviewed studies, commercial products, or clinical trials reference "ugt-55 Antibody." This gap suggests either a nonstandard designation or a hypothetical entity requiring experimental validation.

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

ugt-55; ugt11; T04H1.7; Putative UDP-glucuronosyltransferase ugt-55; UDPGT 55

Target Names

ugt-55

Uniprot No.

Q22180

Target Background

Database Links

STRING: 6239.T04H1.7

UniGene: Cel.39248

Protein Families

UDP-glycosyltransferase family

Subcellular Location

Membrane; Single-pass membrane protein.

Q&A

FAQs for Researchers Investigating UGT-55 Antibody Applications

Advanced Research Questions

How to resolve discrepancies in UGT-55 expression data across studies?
- Analysis framework:
  - Compare antibody clones, epitope regions, and validation methods used (e.g., peptide blocking vs. genetic knockout) .
  - Quantify UGT-55 protein via targeted proteomics (nanoLC-MS) to bypass antibody variability .
  - Evaluate tissue-specific post-translational modifications affecting antibody binding .
What functional assays complement UGT-55 antibody-based detection?
- Pair antibody detection with enzymatic activity assays:
  - Measure glucuronidation rates of probe substrates (e.g., 4-methylumbelliferone) in UGT-55-expressing systems .
  - Use CRISPR-edited cell lines to link UGT-55 protein levels to metabolite clearance .
How to design longitudinal studies assessing UGT-55 regulation in disease models?
- Experimental design:
  - Use multiplex IHC to co-stain UGT-55 with proliferation (Ki67) or hypoxia (HIF-1α) markers .
  - Profile UGT-55 expression in paired pre-/post-treatment biopsies via quantitative immunofluorescence .

Table 1: Comparison of UGT-55 Antibody Validation Techniques

Method	Advantages	Limitations
Western Blot	High specificity with knockout controls	Limited to denatured proteins
Immunofluorescence	Spatial resolution in tissues	Subject to fixation artifacts
NanoLC-MS	Absolute quantification, no antibody bias	Requires specialized instrumentation

Table 2: UGT-55 Functional Assay Conditions

Substrate	Assay Type	Optimal pH	Activity Detection Range
4-OH-Tamoxifen	Glucuronidation	7.4	0.1–5 nmol/min/mg protein
SN-38 (Irinotecan)	Kinetic analysis	6.8	0.05–2 µM Km

Troubleshooting Contradictory Findings

Scenario: Inconsistent UGT-55 localization reports (cytoplasmic vs. nuclear).
- Resolution:
  - Re-evaluate antibody cross-reactivity with paralogs (e.g., UGT2B7) via peptide array .
  - Perform subcellular fractionation followed by Western blot to confirm compartment-specific expression .
Scenario: Variable activity-antibody signal correlation.
- Solution: Normalize antibody-derived protein levels to functional activity data using pooled control samples .

Integration with Genetic Data

For pharmacogenomic studies, genotype-phenotype analyses should pair UGT-55 protein quantification with SNPs in regulatory regions (e.g., promoter/enhancer) using TaqMan assays or WGS .
Example: Reduced UGT-55 activity in UGT2B7 His268Tyr carriers may require dose adjustments in drug metabolism studies .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

ugt-55 Antibody